Tenofovir and its potential in the treatment of hepatitis B virus

Reynaud, Laura; Carleo, Maria Aurora; Talamo, Maria; Borgia, Guglielmo

doi:10.2147/tcrm.s3335

Cited by 7 publications

(3 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, because women affected by active liver disease must continue treatment after delivery, we suggest treatment with an analog that has a high barrier to resistance – namely, tenofovir rather than telbivudine, which has a low barrier to resistance. 47 For simple prophylaxis (to be withdrawn 4 weeks after delivery), both analogs can be used because the duration of treatment is associated with a very low risk of resistance. It is noteworthy that if antivirals are administered during pregnancy, breastfeeding is not recommended because of the potential exposure of infants to these drugs.…”

Section: Discussionmentioning

confidence: 99%

“…Finally, tenofovir is a potent antiviral that acts against HBV with a high barrier to resistance. 47 A retrospective study evaluated the efficacy of tenofovir administered in the third trimester of pregnancy at a dose of 300 mg once daily to eleven women with high viremia (>10 6 copies/mL). 48 The mean maternal viral load declined from 8.87 log 10 copies/mL at baseline to 5.25 log 10 copies/mL at the time of delivery.…”

Section: Antiviral Prophylaxismentioning

confidence: 99%

See 1 more Smart Citation

Vertical transmission of hepatitis B virus: challenges and solutions

Gentile¹,

Borgia²

2014

IJWH

Self Cite

View full text Add to dashboard Cite

More than 240 million people worldwide are chronically infected with hepatitis B virus (HBV). Mother-to-child transmission remains the most important mechanism of infection in countries with a high prevalence of HBV. Universal screening of all pregnant women, at-birth prophylaxis with specific anti-HBV immune globulin, as well as HBV vaccination for newborns of infected mothers are effective in reducing the risk of vertical transmission. However, in cases of a high viral load and hepatitis B e antigen positivity, there is a residual risk of HBV transmission to the newborn despite prophylaxis. This review focuses on the above-indicated strategies and on the efficacy and safety of antiviral drugs administered during the third trimester of pregnancy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Antiviral Prophylaxismentioning

confidence: 99%

Vertical transmission of hepatitis B virus: challenges and solutions

Gentile¹,

Borgia²

2014

IJWH

Self Cite

View full text Add to dashboard Cite

show abstract

“…The treatment offered depends on the viral load (>2000 UI/mL) and whether the patient is carrying HBV DNA (>20,000). The two treatments being prescribed for HCC include NAs) which inhibit the synthesis of DNA or RNA by blocking the replication process, and PEGylated interferon‐alpha (PegIFN‐α) 31 . Host risk factors associated with HCC are being older than 40 years, consuming high levels of alcohol, being male, taking immunosuppressive drugs or being infected with HIV.…”

Section: Discussionmentioning

confidence: 99%

Analysis of hepatocellular carcinoma associated with hepatitis B virus

Zheng

2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

The hepatitis B virus (HBV) is considered one of the main driving forces in the development of hepatocellular carcinoma (HCC). Human HBV is a partially double‐stranded DNA (dsDNA) virus consisting of approximately 3.2 kbp. HBV predominantly infects hepatocytes via the receptor sodium taurocholate cotransporting polypeptide (NTCP) and coreceptor hepatic proteoglycan. The replication of HBV in hepatocytes leads to apoptosis while simultaneously leading to cirrhosis and cancer. Although the integration of dsDNA into the hepatocyte genome seems to be the main cause of mutation, since the discovery of their function, viral proteins have been shown to regulate the P53 pathway or P13K/AKT pathway to prevent host cell apoptosis, causing uncontrolled proliferation of liver cells leading to the formation of solid tumours. The most common treatments involve nucleo(s)tide analogue (NA) and polyethylene glycol (PEG)ylated interferon‐alpha (PegIFN‐α). NA treatment has been found to be effective for the majority of patients and induces few side effects. Nevertheless, the rate of seroconversion is relatively low. PegIFN treatment is contraindicated during pregnancy and leads to a higher morbidity rate, but the seroconversion rate is high. Since medicines and vaccines have been developed, the incidence and mortality of HBV related to HCC have profoundly decreased compared to those in 2000. This review investigates what can be the potential mechanism that HBV can cause HBV and the treatment used in chronic and acute infection.

show abstract

Recent Updates on Viral Oncogenesis: Available Preventive and Therapeutic Entities

Chowdhary,

Deka,

Panda

et al. 2023

Mol. Pharmaceutics

View full text Add to dashboard Cite

Human viral oncogenesis is a complex phenomenon and a major contributor to the global cancer burden. Several recent findings revealed cellular and molecular pathways that promote the development and initiation of malignancy when viruses cause an infection. Even, antiviral treatment has become an approach to eliminate the viral infections and prevent the activation of oncogenesis. Therefore, for a better understanding, the molecular pathogenesis of various oncogenic viruses like, hepatitis virus, human immunodeficiency viral (HIV), human papillomavirus (HPV), herpes simplex virus (HSV), and Epstein-Barr virus (EBV), could be explored, especially, to expand many potent antivirals that may escalate the apoptosis of infected malignant cells while sparing normal and healthy ones. Moreover, contemporary therapies, such as engineered antibodies antiviral agents targeting signaling pathways and cell biomarkers, could inhibit viral oncogenesis. This review elaborates the recent advancements in both natural and synthetic antivirals to control viral oncogenesis. The study also highlights the challenges and future perspectives of using antivirals in viral oncogenesis.

show abstract

Tenofovir and its potential in the treatment of hepatitis B virus

Cited by 7 publications

References 53 publications

Vertical transmission of hepatitis B virus: challenges and solutions

Vertical transmission of hepatitis B virus: challenges and solutions

Analysis of hepatocellular carcinoma associated with hepatitis B virus

Recent Updates on Viral Oncogenesis: Available Preventive and Therapeutic Entities

Contact Info

Product

Resources

About